Cargando…

Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer

Despite extensive research, the exact mechanisms involved in colorectal cancer (CRC) etiology and pathogenesis remain unclear. This study aimed to examine the correlation between tumor-associated alternative splicing (AS) events and tumor immune infiltration (TII) in CRC. We analyzed transcriptome p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jian-yu, Bi, Yan-yan, Yu, Bian-fang, Wang, Qing-feng, Teng, Dan, Wu, Dong-ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117221/
https://www.ncbi.nlm.nih.gov/pubmed/33996533
http://dx.doi.org/10.3389/fonc.2021.583547
_version_ 1783691551957843968
author Shi, Jian-yu
Bi, Yan-yan
Yu, Bian-fang
Wang, Qing-feng
Teng, Dan
Wu, Dong-ning
author_facet Shi, Jian-yu
Bi, Yan-yan
Yu, Bian-fang
Wang, Qing-feng
Teng, Dan
Wu, Dong-ning
author_sort Shi, Jian-yu
collection PubMed
description Despite extensive research, the exact mechanisms involved in colorectal cancer (CRC) etiology and pathogenesis remain unclear. This study aimed to examine the correlation between tumor-associated alternative splicing (AS) events and tumor immune infiltration (TII) in CRC. We analyzed transcriptome profiling and clinical CRC data from The Cancer Genome Atlas (TCGA) database and lists of AS-related and immune-related signatures from the SpliceSeq and Innate databases, respectively to develop and validate a risk model of differential AS events and subsequently a TII risk model. We then conducted a two-factor survival analysis to study the association between TII and AS risk and evaluated the associations between immune signatures and six types of immune cells based on the TIMER database. Subsequently, we studied the distribution of six types of TII cells in high- and low-risk groups for seven AS events and in total. We obtained the profiles of AS events/genes for 484 patients, which included 473 CRC tumor samples and 41 corresponding normal samples, and detected 22581 AS events in 8122 genes. Exon Skip (ES) (8446) and Mutually Exclusive Exons (ME) (74) exhibited the most and fewest AS events, respectively. We then classified the 433 patients with CRC into low-risk (n = 217) and high-risk (n = 216) groups based on the median risk score in different AS events. Compared with patients with low-risk scores (mortality = 11.8%), patients with high-risk scores were associated with poor overall survival (mortality = 27.6%). The risk score, cancer stage, and pathological stage (T, M, and N) were closely correlated with prognosis in patients with CRC (P < 0.001). We identified 6479 differentially expressed genes from the transcriptome profiles of CRC and intersected 468 differential immune-related signatures. High-AS-risk and high-TII-risk predicted a poor prognosis in CRC. Different AS types were associated with different TII risk characteristics. Alternate Acceptor site (AA) and Alternate Promoter (AP) events directly affected the concentration of CD4T cells, and the level of CD8T cells was closely correlated with Alternate Terminator (AT) and Exon Skip (ES) events. Thus, the concentration of CD4T and CD8T cells in the CRC immune microenvironment was not specifically modulated by AS. However, B cell, dendritic cell, macrophage, and neutrophilic cell levels were strongly correlated with AS events. These results indicate adverse associations between AS event risk levels and immune cell infiltration density. Taken together, our findings show a clear association between tumor-associated alternative splicing and immune cell infiltration events and patient outcome and could form a basis for the identification of novel markers and therapeutic targets for CRC and other cancers in the future.
format Online
Article
Text
id pubmed-8117221
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81172212021-05-14 Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer Shi, Jian-yu Bi, Yan-yan Yu, Bian-fang Wang, Qing-feng Teng, Dan Wu, Dong-ning Front Oncol Oncology Despite extensive research, the exact mechanisms involved in colorectal cancer (CRC) etiology and pathogenesis remain unclear. This study aimed to examine the correlation between tumor-associated alternative splicing (AS) events and tumor immune infiltration (TII) in CRC. We analyzed transcriptome profiling and clinical CRC data from The Cancer Genome Atlas (TCGA) database and lists of AS-related and immune-related signatures from the SpliceSeq and Innate databases, respectively to develop and validate a risk model of differential AS events and subsequently a TII risk model. We then conducted a two-factor survival analysis to study the association between TII and AS risk and evaluated the associations between immune signatures and six types of immune cells based on the TIMER database. Subsequently, we studied the distribution of six types of TII cells in high- and low-risk groups for seven AS events and in total. We obtained the profiles of AS events/genes for 484 patients, which included 473 CRC tumor samples and 41 corresponding normal samples, and detected 22581 AS events in 8122 genes. Exon Skip (ES) (8446) and Mutually Exclusive Exons (ME) (74) exhibited the most and fewest AS events, respectively. We then classified the 433 patients with CRC into low-risk (n = 217) and high-risk (n = 216) groups based on the median risk score in different AS events. Compared with patients with low-risk scores (mortality = 11.8%), patients with high-risk scores were associated with poor overall survival (mortality = 27.6%). The risk score, cancer stage, and pathological stage (T, M, and N) were closely correlated with prognosis in patients with CRC (P < 0.001). We identified 6479 differentially expressed genes from the transcriptome profiles of CRC and intersected 468 differential immune-related signatures. High-AS-risk and high-TII-risk predicted a poor prognosis in CRC. Different AS types were associated with different TII risk characteristics. Alternate Acceptor site (AA) and Alternate Promoter (AP) events directly affected the concentration of CD4T cells, and the level of CD8T cells was closely correlated with Alternate Terminator (AT) and Exon Skip (ES) events. Thus, the concentration of CD4T and CD8T cells in the CRC immune microenvironment was not specifically modulated by AS. However, B cell, dendritic cell, macrophage, and neutrophilic cell levels were strongly correlated with AS events. These results indicate adverse associations between AS event risk levels and immune cell infiltration density. Taken together, our findings show a clear association between tumor-associated alternative splicing and immune cell infiltration events and patient outcome and could form a basis for the identification of novel markers and therapeutic targets for CRC and other cancers in the future. Frontiers Media S.A. 2021-04-29 /pmc/articles/PMC8117221/ /pubmed/33996533 http://dx.doi.org/10.3389/fonc.2021.583547 Text en Copyright © 2021 Shi, Bi, Yu, Wang, Teng and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shi, Jian-yu
Bi, Yan-yan
Yu, Bian-fang
Wang, Qing-feng
Teng, Dan
Wu, Dong-ning
Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer
title Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer
title_full Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer
title_fullStr Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer
title_full_unstemmed Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer
title_short Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer
title_sort alternative splicing events in tumor immune infiltration in colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117221/
https://www.ncbi.nlm.nih.gov/pubmed/33996533
http://dx.doi.org/10.3389/fonc.2021.583547
work_keys_str_mv AT shijianyu alternativesplicingeventsintumorimmuneinfiltrationincolorectalcancer
AT biyanyan alternativesplicingeventsintumorimmuneinfiltrationincolorectalcancer
AT yubianfang alternativesplicingeventsintumorimmuneinfiltrationincolorectalcancer
AT wangqingfeng alternativesplicingeventsintumorimmuneinfiltrationincolorectalcancer
AT tengdan alternativesplicingeventsintumorimmuneinfiltrationincolorectalcancer
AT wudongning alternativesplicingeventsintumorimmuneinfiltrationincolorectalcancer